UniQure Raises $89 Million in a Follow-on Offering - Gilde Healthcare

UniQure Raises $89 Million in a Follow-on Offering

April 14, 2015

Amsterdam, the Netherlands — Gilde Healthcare company uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the pricing of its follow-on public offering of 3,000,000 ordinary shares at $29.50 per ordinary share. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the follow-on public offering are expected to be approximately $82.4 million (€76.5 million). In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. The offering is expected to close on or about April 15, 2015. Leerink Partners LLC, Cowen and Company, LLC, and Piper Jaffray & Co. are acting as the joint book-running managers for the offering.

uniQure went public on 5th February 2014 at an introduction price of $17.00 per ordinary share. Last week, uniQure announced a strategic multibillion dollar collaboration with Bristol-Myers Squibb (NYSE:BMY) providing exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases. Gilde Healthcare has supported uniQure since its inception as a spin-out from the Academic Medical Center (AMC) in Amsterdam until its listing at NASDAQ.

About uniQure

uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. The company developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. uniQure engaged in multiple partnerships and has obtained regulatory approval of its lead product, Glybera, in the European Union for a subset of patients with LPLD. uniQure’s product pipeline of gene therapy products in development comprise hemophilia B, acute intermittent porphyria, Parkinson’s disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world’s first stable and scalable AAV manufacturing platform.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, United States) is a private equity investor focused on fast growing healthcare businesses. It manages €550 million across five specialized funds. The Gilde Healthcare I, II and III technology funds target companies developing medicines, medical devices and home & digital health solutions in Europe and the US. The Gilde Healthcare Services funds I and II focus on healthcare service providers, such as specialist clinics, elderly care, primary care, mental health, outsourcing services, medical product suppliers and other healthcare service providers in the Benelux and Germany.

Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta...
September 26, 2022

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022